EGFR and gastric adenocarcinoma: In a cohort of 950 patients with treatment-naïve gastric adenocarcinoma, 63.1% of tumors expressed at least one receptor tyrosine kinase (HER2, EGFR, MET, FGFR2), while 22.7% of these simultaneously expressed multiple biomarkers [36].